Cholbam 2021 U.S. PROMOTIONAL AUDIT REPORT

Published July 2022 • 24 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Cholbam through reportable promotional activity in 2021 to drive use within the Bile Acid Synthesis Disorders, Peroxisomal Disorders, and Zellweger Syndrome markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Travere Therapeutics’s depth of coverage vary within key specialties (e.g., Pediatric Medicine, Neurology, Ophthalmology, Medical Genetics, and Cardiology) and how does this compare to the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Cholbam throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Cholbam in 2021?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 1,020 paid interactions across 540 physicians made on behalf of Cholbam were carefully examined to support our analysis.